Company
Headquarters: San Francisco, CA, United States
Employees: 2
CEO: Ms. Anne Kirby
$135,405
USD as of Jan. 1, 2024
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a CCR5 antagonist to treat multi-drug resistant HIV infection. The company is based in New York, New York. Regnum Corp. is a subsidiary of Phoenixus AG.
Top 1-year algo backtest: +287.69%
$10,000 in March 2023 would now be $38,769 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Regnum Corp has the following listings and related stock indices.
Stock: OTC: RGMP wb_incandescent
Headquarters:
765 Beach Street
Suite 200
San Francisco, CA 94109
United States
Phone: 844 496 6539